Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...

If you pay more attention to how fast yields can grow, then it's worth buying dividend stocks you can forget about for decades.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Dems accept shutdown deal without ACA guarantee; RFK Jr. wades into menopause treatment fray; Novo shares rise despite loss ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 ...

Wall Street closed sharply higher on Monday, driven by strong rebounds in major artificial intelligence (AI) and technology ...

Wendy’s plans to close hundreds of US restaurants over the next few months in an effort to boost its profit. The Dublin, Ohio ...